PL2970412T3 - Aktywacja bioluminescencji przez dopełnienie strukturalne - Google Patents
Aktywacja bioluminescencji przez dopełnienie strukturalneInfo
- Publication number
- PL2970412T3 PL2970412T3 PL14769752.8T PL14769752T PL2970412T3 PL 2970412 T3 PL2970412 T3 PL 2970412T3 PL 14769752 T PL14769752 T PL 14769752T PL 2970412 T3 PL2970412 T3 PL 2970412T3
- Authority
- PL
- Poland
- Prior art keywords
- bioluminscence
- activation
- structural complement
- complement
- structural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0283—Price estimation or determination
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/06—Buying, selling or leasing transactions
- G06Q30/0601—Electronic shopping [e-shopping]
- G06Q30/0631—Item recommendations
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/30—Services specially adapted for particular environments, situations or purposes
- H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/30—Services specially adapted for particular environments, situations or purposes
- H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Business, Economics & Management (AREA)
- Development Economics (AREA)
- Finance (AREA)
- Accounting & Taxation (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791549P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/026354 WO2014151736A1 (en) | 2013-03-15 | 2014-03-13 | Activation of bioluminescence by structural complementation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2970412T3 true PL2970412T3 (pl) | 2022-11-14 |
Family
ID=51581027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL14769752.8T PL2970412T3 (pl) | 2013-03-15 | 2014-03-13 | Aktywacja bioluminescencji przez dopełnienie strukturalne |
PL20197758.4T PL3783011T3 (pl) | 2013-03-15 | 2014-03-13 | Aktywacja bioluminescencji przez dopełnienie strukturalne |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20197758.4T PL3783011T3 (pl) | 2013-03-15 | 2014-03-13 | Aktywacja bioluminescencji przez dopełnienie strukturalne |
Country Status (15)
Country | Link |
---|---|
US (10) | US9797890B2 (pl) |
EP (4) | EP3783011B1 (pl) |
JP (4) | JP6654557B2 (pl) |
KR (3) | KR20230079494A (pl) |
CN (2) | CN105143249A (pl) |
AU (3) | AU2014236949C1 (pl) |
BR (1) | BR112015023394B8 (pl) |
CA (1) | CA2906063A1 (pl) |
DK (2) | DK2970412T5 (pl) |
ES (2) | ES2929362T3 (pl) |
IL (3) | IL286816B (pl) |
PL (2) | PL2970412T3 (pl) |
PT (2) | PT2970412T (pl) |
SG (2) | SG10201601929YA (pl) |
WO (1) | WO2014151736A1 (pl) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3783011B1 (en) * | 2013-03-15 | 2022-09-21 | Promega Corporation | Activation of bioluminescence by structural complementation |
US20230342826A1 (en) * | 2013-03-15 | 2023-10-26 | Promega Corporation | Activation of bioluminescence by structural complementation |
EP4219736A1 (en) * | 2014-09-12 | 2023-08-02 | Promega Corporation | Internal protein tags |
US11365402B2 (en) | 2014-09-12 | 2022-06-21 | Promega Corporation | Internal protein tags |
EP3254113B1 (en) | 2015-02-05 | 2024-10-09 | Promega Corporation | Luciferase-based thermal shift assays |
US10634680B2 (en) | 2016-04-26 | 2020-04-28 | University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
KR102556363B1 (ko) * | 2016-10-20 | 2023-07-18 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 보툴리눔 신경독소의 활성을 측정하기 위한 시험관내 및 세포 기반 검정 |
CA3022981A1 (en) * | 2017-11-01 | 2019-05-01 | Queen's University At Kingston | Hippo pathway bioluminescent biosensor |
JP7248693B2 (ja) * | 2018-02-26 | 2023-03-29 | テクニーシェ・ユニバーシタイト・アイントホーベン | 溶液中の生物分子またはリガンドを検出し、定量化する生物発光バイオセンサー |
EP4140991B1 (en) | 2018-06-01 | 2024-05-15 | Promega Corporation | Inhibitors of oplophorus luciferase-derived bioluminescent complexes |
WO2019241438A2 (en) * | 2018-06-12 | 2019-12-19 | Promega Corporation | Multipartite luciferase |
US10962538B2 (en) | 2018-06-14 | 2021-03-30 | The Trustees Of Columbia University In The City Of New York | Assays using arrestin recruitment and unmodified receptors |
JP7447101B2 (ja) | 2018-10-03 | 2024-03-11 | プロメガ コーポレイション | セレンテラジンならびにその類似体及び誘導体を安定化させるための組成物及び方法 |
JP2022509200A (ja) | 2018-11-28 | 2022-01-20 | プロメガ コーポレイション | 反応性ペプチド標識付け |
WO2020117954A2 (en) | 2018-12-04 | 2020-06-11 | Promega Corporation | Broad spectrum gpcr binding agents |
WO2020191339A1 (en) | 2019-03-20 | 2020-09-24 | Promega Corporation | Photoaffinity probes |
SG11202110773RA (en) * | 2019-04-10 | 2021-10-28 | Promega Corp | Compositions and methods for analyte detection using bioluminescence |
US11360096B2 (en) | 2019-05-16 | 2022-06-14 | Duke University | Complex BRET technique for measuring biological interactions |
JP7650829B2 (ja) | 2019-06-24 | 2025-03-25 | プロメガ コーポレイション | 細胞中に生体分子を送達するための修飾ポリアミンポリマー |
DE102019127894B4 (de) * | 2019-10-16 | 2022-05-12 | Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh | Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts |
WO2021102434A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Split-enzyme system to detect specific dna in living cells |
EP4065699A1 (en) | 2019-11-27 | 2022-10-05 | Promega Corporation | Multipartite luciferase peptides and polypeptides |
JP2023506486A (ja) | 2019-12-10 | 2023-02-16 | プロメガ コーポレイション | 多官能性プローブを使用する生物発光検出用組成物及び生物発光検出方法 |
EP4127148A1 (en) | 2020-03-25 | 2023-02-08 | Erasmus University Rotterdam Medical Center | Reporter system for radionuclide imaging |
US20230257726A1 (en) * | 2020-05-11 | 2023-08-17 | Chan Zuckerberg Biohub, Inc. | Ace2 compositions and methods |
EP4153770A2 (en) | 2020-05-22 | 2023-03-29 | Promega Corporation | Enhancement of kinase target engagement |
EP4204808A1 (en) | 2020-08-28 | 2023-07-05 | Promega Corporation | Target engagement assay for ras proteins |
US20240252689A1 (en) * | 2021-05-18 | 2024-08-01 | The Board Of Regents Of The University Of Texas System | Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents |
WO2023215452A2 (en) | 2022-05-04 | 2023-11-09 | Promega Corporation | Split modified dehalogenase variants |
WO2023215432A1 (en) | 2022-05-04 | 2023-11-09 | Promega Corporation | Circularly permuted dehalogenase variants |
US20240132859A1 (en) | 2022-05-04 | 2024-04-25 | Promega Corporation | Modified dehalogenase with extended surface loop regions |
WO2023215497A1 (en) | 2022-05-04 | 2023-11-09 | Promega Corporation | Photoactivatable compounds and uses thereof |
WO2024151471A1 (en) | 2023-01-09 | 2024-07-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-throughput assay based on ligand-biased structural dynamics response |
WO2024217577A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳琅技生命科技有限公司 | 一种肽以及含有该肽的发光复合物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
US5914095A (en) | 1989-04-07 | 1999-06-22 | Salutar, Inc. | Polychelants containg amide bonds |
EP0664819B1 (en) | 1992-10-14 | 1997-08-06 | Nycomed Imaging As | Chelating polymers |
US5756688A (en) | 1992-10-14 | 1998-05-26 | Sterling Winthrop Inc. | MR imaging compositions and methods |
GB9503969D0 (en) | 1995-02-28 | 1995-04-19 | Sams Bernard | Incrementing mechanism |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US5879739A (en) | 1997-02-20 | 1999-03-09 | Tower Semiconductor Ltd. | Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer |
JP4613441B2 (ja) * | 2000-04-26 | 2011-01-19 | チッソ株式会社 | 新規ルシフェラーゼおよび発光蛋白質 |
DE60142761D1 (de) * | 2000-04-26 | 2010-09-23 | Chisso Corp | Oplophorus Luciferase |
US20040181830A1 (en) | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US7008642B1 (en) | 2001-02-12 | 2006-03-07 | Advanced Cardiovascular Systems, Inc. | Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same |
US7195884B2 (en) | 2002-07-19 | 2007-03-27 | Promega Corp. | Methods and kits for transferases |
WO2004029284A2 (en) * | 2002-09-30 | 2004-04-08 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
US7237811B1 (en) * | 2005-04-20 | 2007-07-03 | Lawrence Barry G | Casement window latch assembly |
US20090149338A1 (en) | 2005-09-30 | 2009-06-11 | Hughes Thomas E | System for detecting protein-protein interactions |
US7601517B2 (en) | 2006-01-10 | 2009-10-13 | Stanford University | Split protein self complementing fragments, systems, and methods of use thereof |
US20130332133A1 (en) | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
US20090075313A1 (en) | 2007-05-04 | 2009-03-19 | Stanford University | Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems |
WO2009058364A1 (en) * | 2007-11-01 | 2009-05-07 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Cell-free methods for detecting protein-ligand interctions |
WO2009065002A1 (en) * | 2007-11-15 | 2009-05-22 | Endocyte, Inc. | Method of administering conjugates |
JP5582505B2 (ja) | 2009-02-09 | 2014-09-03 | Jnc株式会社 | セレンテラジン類縁体及びその製造方法 |
EP2420573A1 (en) | 2009-04-17 | 2012-02-22 | National Institute of Advanced Industrial Science And Technology | Stable artificial bioluminescent enzyme having super-high brightness |
SG175180A1 (en) | 2009-05-01 | 2011-11-28 | Promega Corp | Synthetic oplophorus luciferases with enhanced light output |
SG10202103336SA (en) * | 2010-11-02 | 2021-04-29 | Promega Corp | Novel coelenterazine substrates and methods of use |
US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
CA2894435A1 (en) * | 2012-12-12 | 2014-06-19 | Promega Corporation | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
EP3783011B1 (en) | 2013-03-15 | 2022-09-21 | Promega Corporation | Activation of bioluminescence by structural complementation |
EP4219736A1 (en) * | 2014-09-12 | 2023-08-02 | Promega Corporation | Internal protein tags |
-
2014
- 2014-03-13 EP EP20197758.4A patent/EP3783011B1/en active Active
- 2014-03-13 PL PL14769752.8T patent/PL2970412T3/pl unknown
- 2014-03-13 CN CN201480015213.XA patent/CN105143249A/zh active Pending
- 2014-03-13 WO PCT/US2014/026354 patent/WO2014151736A1/en active Application Filing
- 2014-03-13 IL IL286816A patent/IL286816B/en unknown
- 2014-03-13 CA CA2906063A patent/CA2906063A1/en active Pending
- 2014-03-13 SG SG10201601929YA patent/SG10201601929YA/en unknown
- 2014-03-13 EP EP22196592.4A patent/EP4169935A1/en active Pending
- 2014-03-13 AU AU2014236949A patent/AU2014236949C1/en active Active
- 2014-03-13 JP JP2016502113A patent/JP6654557B2/ja active Active
- 2014-03-13 US US14/209,610 patent/US9797890B2/en active Active
- 2014-03-13 US US14/209,546 patent/US9797889B2/en active Active
- 2014-03-13 PT PT147697528T patent/PT2970412T/pt unknown
- 2014-03-13 KR KR1020237017712A patent/KR20230079494A/ko active Pending
- 2014-03-13 CN CN202310649630.0A patent/CN117024548A/zh active Pending
- 2014-03-13 PL PL20197758.4T patent/PL3783011T3/pl unknown
- 2014-03-13 PT PT201977584T patent/PT3783011T/pt unknown
- 2014-03-13 EP EP14769752.8A patent/EP2970412B1/en active Active
- 2014-03-13 EP EP22182344.6A patent/EP4177261A1/en active Pending
- 2014-03-13 KR KR1020217008951A patent/KR102675860B1/ko active Active
- 2014-03-13 DK DK14769752.8T patent/DK2970412T5/da active
- 2014-03-13 BR BR112015023394A patent/BR112015023394B8/pt active IP Right Grant
- 2014-03-13 ES ES20197758T patent/ES2929362T3/es active Active
- 2014-03-13 ES ES14769752T patent/ES2926463T3/es active Active
- 2014-03-13 KR KR1020157024687A patent/KR20150129721A/ko not_active Ceased
- 2014-03-13 DK DK20197758.4T patent/DK3783011T5/da active
- 2014-03-13 SG SG11201507306VA patent/SG11201507306VA/en unknown
-
2015
- 2015-09-01 IL IL240985A patent/IL240985B/en active IP Right Grant
-
2016
- 2016-03-17 US US15/073,249 patent/US9869670B2/en active Active
-
2017
- 2017-09-27 US US15/717,534 patent/US10107800B2/en active Active
-
2018
- 2018-02-19 US US15/899,219 patent/US10184936B2/en active Active
- 2018-06-29 US US16/023,972 patent/US10288605B2/en active Active
- 2018-07-13 US US16/035,117 patent/US10648971B2/en active Active
- 2018-10-31 AU AU2018256548A patent/AU2018256548B2/en active Active
-
2020
- 2020-01-30 JP JP2020013133A patent/JP7280842B2/ja active Active
- 2020-04-16 IL IL273989A patent/IL273989B/en unknown
- 2020-04-17 US US16/851,841 patent/US11493504B2/en active Active
- 2020-08-04 AU AU2020213288A patent/AU2020213288B2/en active Active
-
2023
- 2023-01-13 JP JP2023004036A patent/JP7532562B2/ja active Active
-
2024
- 2024-07-31 JP JP2024124929A patent/JP2024167207A/ja active Pending
- 2024-09-19 US US18/890,453 patent/US20250022022A1/en active Pending
- 2024-09-23 US US18/893,549 patent/US20250045806A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301252I2 (nl) | tislelizumab | |
NL301278I2 (nl) | vadadustat | |
PL2970412T3 (pl) | Aktywacja bioluminescencji przez dopełnienie strukturalne | |
DK3342773T3 (da) | Syk-hæmmere | |
DK3613453T3 (da) | Fordamper | |
DK2978844T3 (da) | Modificerede tgf-beta2-oligonukleotider | |
HRP20171890T1 (hr) | Supstituirani imidazopiridazini | |
DK3077047T3 (da) | Aramcholsalte | |
DK2956698T5 (da) | Bindestrimler | |
DK3060460T3 (da) | Saddel | |
DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
EP2952513A4 (en) | AZOLE AND BENZENE DERIVATIVE | |
EP2945942A4 (en) | Voriconazole IMMUNOASSAY | |
DK3052081T3 (da) | Pastil | |
DK2946640T3 (da) | Langmuir-probe | |
EP2969096A4 (en) | Bottle pressurization delivery system | |
EP2991647A4 (en) | DEUTERED AMLEXANOX | |
EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
EP2970310A4 (en) | 5-BROMO-indirubins | |
DE102013106534B8 (de) | Chromatographiepipettenspitze | |
DK3071227T3 (da) | Fiskevaccine | |
FI20136125A (fi) | Rumpupulpperi | |
DE112014001252A5 (de) | Aufbissschiene | |
DK2981168T3 (da) | Laminitiskile | |
DK3086679T3 (da) | Sportssko |